Literature DB >> 3772373

Distribution of glial fibrillary acidic protein in gliosed human white matter.

J Newcombe, M N Woodroofe, M L Cuzner.   

Abstract

Glial fibrillary acidic protein (GFAP) in gliosed white matter from multiple sclerosis plaques and cerebral infarcts was examined by polyacrylamide gel electrophoresis and immunoblotting. Using a monoclonal antibody raised against human GFAP, up to 11 GFAP polypeptide bands of molecular weight 37-49 kilodaltons were identified in particulate and supernatant fractions of CNS tissue homogenates. Soluble GFAP constituted about one-quarter of the total GFAP in normal cerebral white matter. In brain lesions in which reactive astrocytes were observed microscopically, the proportion of soluble GFAP was increased, with a greater representation of the lower-molecular-weight forms. In brain chronic sclerotic plaques, almost all of the GFAP was in the particulate form. Purified particulate GFAP was susceptible to proteolysis at acid but not at neutral pH in the presence of CNS homogenates. In tissue autolysis studies, GFAP was stable in situ for periods well in excess of average CNS postmortem times.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3772373     DOI: 10.1111/j.1471-4159.1986.tb13079.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

1.  Traumatically injured astrocytes release a proteomic signature modulated by STAT3-dependent cell survival.

Authors:  Jaclynn Levine; Eunice Kwon; Pablo Paez; Weihong Yan; Gregg Czerwieniec; Joseph A Loo; Michael V Sofroniew; Ina-Beate Wanner
Journal:  Glia       Date:  2015-12-19       Impact factor: 7.452

2.  A novel metalloproteinase originally isolated from brain myelin membranes is present in many tissues.

Authors:  A Chantry; P Glynn
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

3.  The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement.

Authors:  S J Piddlesden; H Lassmann; F Zimprich; B P Morgan; C Linington
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

4.  Relative stabilities of wild-type and mutant glial fibrillary acidic protein in patients with Alexander disease.

Authors:  Michael R Heaven; Landon Wilson; Stephen Barnes; Michael Brenner
Journal:  J Biol Chem       Date:  2019-09-04       Impact factor: 5.157

5.  Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects.

Authors:  J A Laurence; S H Fatemi
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

6.  Magnetisation transfer ratio analysis of normal appearing white matter in patients with familial and sporadic multiple sclerosis.

Authors:  M Siger-Zajdel; K Selmaj
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 7.  Gastrointestinal mucosal biopsies in Parkinson's disease: beyond alpha-synuclein detection.

Authors:  Pascal Derkinderen; François Cossais; Adrien de Guilhem de Lataillade; Laurène Leclair-Visonneau; Michel Neunlist; Sébastien Paillusson; Roberto De Giorgio
Journal:  J Neural Transm (Vienna)       Date:  2021-11-24       Impact factor: 3.850

8.  Monoclonal antibody 14E recognizes an antigen common to human oligodendrocytes, Schwann cells, Bergmann glia, and a subpopulation of reactive glia.

Authors:  J Newcombe; N Naik; M L Cuzner
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

9.  Astrogliosis and behavioral changes in mice lacking the neutral cysteine protease bleomycin hydrolase.

Authors:  S E Montoya; E Thiels; J P Card; J S Lazo
Journal:  Neuroscience       Date:  2007-03-27       Impact factor: 3.590

10.  Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology.

Authors:  Axel Petzold; Djordje Gveric; Mike Groves; Klaus Schmierer; Donna Grant; Miles Chapman; Geoffrey Keir; Louise Cuzner; Edward J Thompson
Journal:  Exp Neurol       Date:  2008-06-20       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.